We are live on ! Find out more
ACA

Acorn Capital Advisors Portfolio holdings

AUM $352M
1-Year Est. Return 299.18%
This Fund
S&P 500
This Quarter Est. Return
+3.01%
1 Year Est. Return
+299.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$153M
AUM Growth
+$2.95M
Cap. Flow
+$971K
Cap. Flow %
0.63%
Top 10 Hldgs %
83.28%
Holding
22
New
–
Increased
7
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
OKUR
OnKure Therapeutics
OKUR
+$3.67M
2
CADL icon
Candel Therapeutics
CADL
+$2.2M
3
TARA icon
Protara Therapeutics
TARA
+$1.63M
4
YMAB
Y-mAbs Therapeutics
YMAB
+$825K
5
PBYI icon
Puma Biotechnology
PBYI
+$610K

Top Sells

Rank Stock Value
1
OPTN
OptiNose
OPTN
+$3.88M
2
URGN icon
UroGen Pharma
URGN
+$2.46M
3
MURA
Mural Oncology
MURA
+$1.45M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$368K
5
CRDF icon
Cardiff Oncology
CRDF
+$102K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.28B
$29.4M 19.24%
1,131,501
– –
URGN icon
2
UroGen Pharma
URGN
$1.86B
$17.3M 11.29%
1,259,749
-256,554
-17% -$2.46M
YMAB
3
DELISTED
Y-mAbs Therapeutics
YMAB
$15.4M 10.09%
3,418,995
+183,608
+6% +$825K
PBYI icon
4
Puma Biotechnology
PBYI
$404M
$14.2M 9.27%
4,131,299
+191,247
+5% +$610K
CADL icon
5
Candel Therapeutics
CADL
$733M
$13.1M 8.54%
2,580,517
+428,265
+20% +$2.2M
TRVI icon
6
Trevi Therapeutics
TRVI
$2.59B
$11.7M 7.67%
2,144,844
– –
TERN
7
DELISTED
Terns Pharmaceuticals
TERN
$7.35M 4.81%
1,971,264
– –
OKUR
8
OnKure Therapeutics
OKUR
$154M
$6.79M 4.44%
2,839,674
+1,400,000
+97% +$3.67M
HELP
9
Cybin Inc
HELP
$485M
$6.16M 4.03%
734,394
– –
BCAX
10
Bicara Therapeutics
BCAX
$1.78B
$5.98M 3.91%
643,382
– –
TARA icon
11
Protara Therapeutics
TARA
$220M
$5.31M 3.47%
1,752,115
+472,315
+37% +$1.63M
CRDF icon
12
Cardiff Oncology
CRDF
$66.5M
$4.44M 2.9%
1,408,767
-33,541
-2% -$102K
AURA icon
13
Aura Biosciences
AURA
$725M
$3.73M 2.44%
595,744
+5,236
+0.9% +$30.6K
VSTM icon
14
Verastem
VSTM
$510M
$3.23M 2.12%
779,498
– –
WHWK
15
Whitehawk Therapeutics
WHWK
$190M
$2.13M 1.39%
1,139,363
– –
BCAB icon
16
BioAtla
BCAB
$5.46M
$1.91M 1.25%
96,702
+16,061
+20% +$326K
MURA
17
DELISTED
Mural Oncology
MURA
$1.61M 1.06%
653,779
-615,936
-49% -$1.45M
YARW
18
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$1.22M 0.79%
14,731
-988
-6% -$64.2K
QTTB icon
19
Q32 Bio
QTTB
$466M
$1.2M 0.78%
803,425
– –
ACRV icon
20
Acrivon Therapeutics
ACRV
$64.2M
$482K 0.32%
405,237
– –
XFOR icon
21
X4 Pharmaceuticals
XFOR
$375M
$292K 0.19%
153,730
-89,958
-37% -$368K
OPTN
22
DELISTED
OptiNose
OPTN
– –
-422,814
Closed -$3.88M

Similar funds

PIC
PCJ Investment Counsel Toronto, Ontario, Canada $352M AUM 68.32% 1-Year Est. Return
HIA
HTG Investment Advisors New Canaan, Connecticut $352M AUM 17.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
EC
Elmind Capital New York $352M AUM
AW
Alaethes Wealth Glenbrook, Nevada $351M AUM 22.79% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
FWM
ForthRight Wealth Management Alpharetta, Georgia $353M AUM 12.98% 1-Year Est. Return
BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Acorn Capital Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Acorn Capital Advisors held 22 positions worth $153M, up 2% from $150M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 4.5%. Acorn Capital Advisors opened no new positions and exited 1, leaving the 22-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Acorn Capital Advisors added most to OnKure Therapeutics in Q2 2025, an estimated $3.67M increase.
  • Acorn Capital Advisors's biggest Q2 2025 reduction was UroGen Pharma, cutting an estimated $2.46M.
  • Acorn Capital Advisors fully exited OptiNose in Q2 2025, selling an estimated $3.88M.
  • Acorn Capital Advisors's ten largest holdings make up 83% of its $153M portfolio in Q2 2025.
  • Acorn Capital Advisors opened 0 new positions and closed 1 in Q2 2025.
  • Acorn Capital Advisors's portfolio value rose 2% quarter-over-quarter to $153M.

Based on Acorn Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.